Pharmacokinetics and bioavailability of drotaverine in humans

被引:22
作者
Bolaji, OO
Onyeji, CO
Ogundaini, AO
Olugbade, TA
Ogunbona, FA
机构
[1] Dept. of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife
关键词
drotaverine HCl; pharmacokinetics; bioavailability; human;
D O I
10.1007/BF03189716
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics and bioavailability of drotaverine was studied in 10 healthy volunteers after administration of single 80 mg oral and intravenous doses of the HCl salt of the drug, in a crossover fashion. Plasma and urine samples were analyzed for the unchanged drug by HPLC. The pharmacokinetic parameters, such as elimination half-life, plasma clearance, renal clearance and apparent volume of distribution, were not influenced by the route of drug administration. The drug was mainly eliminated by non-renal routes since renal clearance accounted for only 0.31 +/- 0.13% of the total plasma clearance. The absolute bioavailability was variable and ranged from 24.5-91% with a mean of 58.2 +/- 18.2% (mean +/- SD). It is suggested that the high variation in the bioavailability of drotaverine HCl after oral administration may result in significant interindividual differences in therapeutic response.
引用
收藏
页码:217 / 221
页数:5
相关论文
共 14 条
[1]   VARIABLE BIOAVAILABILITY OF PAPAVERINE [J].
BERG, G ;
JONSSON, KA ;
HAMMAR, M ;
NORLANDER, B .
PHARMACOLOGY & TOXICOLOGY, 1988, 62 (05) :308-310
[2]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF DROTAVERINE IN HUMAN PLASMA AND URINE [J].
BOLAJI, OO ;
ONYEJI, CO ;
OGUNGBAMILA, FO ;
OGUNBONA, FA ;
OGUNLANA, EO .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1993, 622 (01) :93-97
[3]  
GARRETT ER, 1978, INT J CLIN PHARM BI, V16, P193
[4]   MODIFIED HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR ANALYSIS OF DROTAVERINE IN HUMAN PLASMA [J].
LALLA, JK ;
SHAH, MU ;
JAIN, MB ;
SHARMA, AH .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1993, 11 (4-5) :385-388
[5]  
MAGYAR K, 1978, ACTA PHYSIOL HUNG, V51, P401
[6]  
MCEVOY GK, 1989, AHFS DRUG INFORMATIO, P941
[7]  
MESZAROS Z, 1967, Patent No. 3337539
[8]   INFLUENCE OF DOSAGE FORM ON PAPAVERINE BIOAVAILABILITY [J].
MEYER, MC ;
GOLLAMUDI, R ;
STRAUGHN, AB .
JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 19 (8-9) :435-444
[9]   A NEW METHOD FOR HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF DROTAVERINE IN PLASMA [J].
MEZEI, J ;
KUTTEL, S ;
SZENTMIKLOSI, P ;
MARTON, S ;
RACZ, I .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (10) :1489-1491
[10]  
RUTZCOUDRAY MH, 1976, PHARM ACTA HELV, V51, P258